Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
BBIO Stock Summary
Top 10 Correlated ETFs
BBIO
In the News
BridgeBio Pharma, Bayer agree on licensing deal for heart disease drug in Europe
BridgeBio Pharma has granted German drugmaker Bayer an exclusive license to commercialize its heart disease drug in Europe, the companies said on Monday.
BridgeBio, A Top 3% Biotech, Just Snagged A $310 Million Deal; Will Shares Break Out?
Bayer snagged commercial rights to BridgeBio's lead asset, acoramidis, in Europe for $310 million. BridgeBio stock is nearing a breakout.
BridgeBio Pharma (BBIO) Reports Q4 Loss, Lags Revenue Estimates
BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.96 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to loss of $0.87 per share a year ago.
Analysts Estimate BridgeBio Pharma (BBIO) to Report a Decline in Earnings: What to Look Out for
BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Groundbreaking Biotech Stocks to Invest in Now
Biotechnology companies are intriguing investment vehicles because they are part of a pretty speculative industry that allows investors to grow their investments rapidly — if they pick a company before it releases positive results. But on the flip side, a single negative press release could send a stock tumbling with biotech stocks being so volatile.
BridgeBio Pharma: FDA Submission Acromidis And Top Line Results On Deck
BridgeBio Pharma, Inc. expects results from the phase 1/2 study, using gene therapy BBP-631 for the treatment of patients with congenital adrenal hyperplasia, in early 2024. The congenital adrenal hyperplasia treatment market is expected to reach $892 million by 2033. Potential FDA acceptance of regulatory application of acromidis for the treatment of patients with ATTR-CM, expected within 60 days after submission achieved December 5th of 2023.
BridgeBio Pharma's Robust Pipeline Could Benefit From A Partner
BridgeBio's FDA filing for acoramidis and advances in KRAS mutation cancer treatment contrast with growing financial losses. Acoramidis competes with Pfizer's ATTR-CM treatments; BBIO's oncology focus includes promising KRAS inhibitors and RAS-targeting strategies. Financially, the Company reports increased net loss and share count, yet possesses a solid short-term solvency with high long-term debts.
2 Biotechs That Could Get Bought Out in 2024
With several big pharmas set to lose patent protection for key drugs this decade, the merger and acquisition scene is widely expected to heat up in 2024. These two biotechs have repeatedly been rumored to be receiving takeover interest from larger peers.
3 Russell 2000 Stocks That Are About to Get Absolutely Crushed
For most of the year, the Russell 2000 has lagged far behind its peers, the S&P500 and the Nasdaq. However, the small-to-mid cap index appears to be closing the gap.
BridgeBio Pharma to Present Additional Data from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American Heart Association (AHA) Scientific Sessions 2023
PALO ALTO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that additional Phase 3 data on clinical outcomes from ATTRibute-CM, its study of acoramidis in ATTR-CM will be presented at the AHA Scientific Sessions 2023, taking place in Philadelphia, Pennsylvania on November 11 - 13, 2023. As previously announced, a highly statistically significant result was observed on the primary endpoint of ATTRibute-CM with a Win Ratio of 1.8 (p
BBIO Financial details
BBIO Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.39 | 0.07 | 0.48 | 0.53 | 0 | |
Net income per share | -2.48 | -4.1 | -4.43 | -3.35 | 0 | |
Operating cash flow per share | -2.41 | -3.39 | -3.45 | -2.84 | 0 | |
Free cash flow per share | -2.46 | -3.45 | -3.78 | -2.89 | 0 | |
Cash per share | 5.2 | 5.15 | 5.8 | 3.2 | 0 | |
Book value per share | 3.89 | 0.49 | -6.03 | -8.51 | -0.01 | |
Tangible book value per share | 4.53 | 0.91 | -6.31 | -8.64 | -0.01 | |
Share holders equity per share | 3.89 | 0.49 | -6.03 | -8.51 | -0.01 | |
Interest debt per share | 1.11 | 4.51 | 12.32 | 12.26 | 0.01 | |
Market cap | 3.68B | 8.39B | 2.41B | 1.12B | 6571.89B | |
Enterprise value | 3.42B | 8.53B | 3.74B | 2.47B | 6573.26B | |
P/E ratio | -14.14 | -17.34 | -3.77 | -2.27 | -10.22K | |
Price to sales ratio | 90.82 | 1.02K | 34.54 | 14.47 | 706.43K | |
POCF ratio | -14.53 | -20.99 | -4.84 | -2.68 | -12.45K | |
PFCF ratio | -14.24 | -20.6 | -4.41 | -2.64 | -12.42K | |
P/B Ratio | 9.02 | 144.9 | -2.77 | -0.9 | -4.85K | |
PTB ratio | 9.02 | 144.9 | -2.77 | -0.9 | -4.85K | |
EV to sales | 84.31 | 1.03K | 53.65 | 31.82 | 706.57K | |
Enterprise value over EBITDA | -12.24 | -18.19 | -6.93 | -6.99 | -11.44K | |
EV to operating cash flow | -13.49 | -21.34 | -7.51 | -5.89 | -12.46K | |
EV to free cash flow | -13.22 | -20.95 | -6.85 | -5.8 | -12.43K | |
Earnings yield | -0.07 | -0.06 | -0.27 | -0.44 | 0 | |
Free cash flow yield | -0.07 | -0.05 | -0.23 | -0.38 | 0 | |
Debt to equity | 0.26 | 8.56 | -1.99 | -1.38 | -1.28 | |
Debt to assets | 0.17 | 0.7 | 1.71 | 2.77 | 3.18 | |
Net debt to EBITDA | 0.94 | -0.3 | -2.47 | -3.81 | -2.37 | |
Current ratio | 11.45 | 7 | 6.45 | 4.29 | 3.32 | |
Interest coverage | -30.38 | -12.94 | -12.39 | -5.87 | -7.47 | |
Income quality | 0.88 | 0.79 | 0.85 | 0.87 | 0.81 | |
Dividend Yield | 0 | 0.06 | 0 | 0 | 0 | |
Payout ratio | 0 | -1.11 | -0.01 | 0 | 0 | |
Sales general and administrative to revenue | 2.33 | 17.66 | 0 | 0 | 0 | |
Research and developement to revenue | 5.18 | 40.86 | 6.51 | 5.19 | 48.99 | |
Intangibles to total assets | 0 | 0 | 0.04 | 0.05 | 0.05 | |
Capex to operating cash flow | 0.02 | 0.02 | 0.1 | 0.02 | 0 | |
Capex to revenue | -0.13 | -0.91 | -0.69 | -0.08 | -0.14 | |
Capex to depreciation | -5.98 | -2.43 | -8.26 | -0.93 | -0.2 | |
Stock based compensation to revenue | 0.53 | 7.09 | 1.43 | 1.18 | 11.69 | |
Graham number | 14.72 | 6.73 | 24.51 | 25.32 | 0.03 | |
ROIC | -0.46 | -0.79 | -0.72 | -0.98 | -1.69 | |
Return on tangible assets | -0.41 | -0.69 | -0.66 | -0.83 | -1.24 | |
Graham Net | 3.71 | 0.1 | -7.35 | -9.25 | -0.01 | |
Working capital | 547.38M | 550.97M | 709.58M | 387.45M | 333.75M | |
Tangible asset value | 475.98M | 107.89M | -910.51M | -1.27B | -1.37B | |
Net current asset value | 444.06M | 47.12M | -1.04B | -1.36B | -1.41B | |
Invested capital | 0.26 | 8.56 | -1.99 | -1.38 | -1.28 | |
Average receivables | 0 | 0 | 9.87M | 18.41M | 9.42M | |
Average payables | 11.18M | 8.9M | 10.41M | 11.72M | 11.11M | |
Average inventory | 0 | 0 | -34.45M | -15.48M | 27.29M | |
Days sales outstanding | 0 | 0 | 103.4 | 80.28 | 68.7 | |
Days payables outstanding | 1.29K | 1.06K | 1.39K | 1.23K | 1.59K | |
Days of inventory on hand | 0 | 0 | -8.08K | 4.03K | 2.49K | |
Receivables turnover | 0 | 0 | 3.53 | 4.55 | 5.31 | |
Payables turnover | 0.28 | 0.35 | 0.26 | 0.3 | 0.23 | |
Inventory turnover | 0 | 0 | -0.05 | 0.09 | 0.15 | |
ROE | -0.64 | -8.36 | 0.73 | 0.39 | 0.47 | |
Capex per share | -0.05 | -0.06 | -0.33 | -0.04 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.01 | 0.01 | 0.01 | 0.03 | 0.01 | |
Net income per share | -1.04 | -1.16 | -0.98 | -1.08 | -0.96 | |
Operating cash flow per share | -0.62 | -0.95 | -0.71 | -0.89 | -0.72 | |
Free cash flow per share | -0.63 | -0.95 | -0.71 | -0.89 | -0.72 | |
Cash per share | 3.16 | 2.89 | 3.96 | 3.33 | 2.49 | |
Book value per share | -8.4 | -8.03 | -8.48 | -7.39 | -7.76 | |
Tangible book value per share | -8.53 | -8.13 | -8.58 | -7.47 | -7.85 | |
Share holders equity per share | -8.4 | -8.03 | -8.48 | -7.39 | -7.76 | |
Interest debt per share | 11.7 | 11.48 | 10.95 | 10.53 | 10.09 | |
Market cap | 1.14B | 2.53B | 2.76B | 4.31B | 7.04B | |
Enterprise value | 2.48B | 3.85B | 4.19B | 5.54B | 8.41B | |
P/E ratio | -1.82 | -3.58 | -4.37 | -6.08 | -10.47 | |
Price to sales ratio | 608.56 | 1.39K | 1.68K | 1.05K | 4.04K | |
POCF ratio | -12.2 | -17.54 | -24.36 | -29.65 | -56.43 | |
PFCF ratio | -12.1 | -17.53 | -24.27 | -29.57 | -56.23 | |
P/B Ratio | -0.91 | -2.06 | -2.03 | -3.57 | -5.2 | |
PTB ratio | -0.91 | -2.06 | -2.03 | -3.57 | -5.2 | |
EV to sales | 1.33K | 2.11K | 2.55K | 1.35K | 4.82K | |
Enterprise value over EBITDA | -22.01 | -32.76 | -31.07 | -35.11 | -49.68 | |
EV to operating cash flow | -26.65 | -26.69 | -36.99 | -38.12 | -67.35 | |
EV to free cash flow | -26.42 | -26.69 | -36.85 | -38.01 | -67.12 | |
Earnings yield | -0.14 | -0.07 | -0.06 | -0.04 | -0.02 | |
Free cash flow yield | -0.08 | -0.06 | -0.04 | -0.03 | -0.02 | |
Debt to equity | -1.38 | -1.41 | -1.28 | -1.44 | -1.28 | |
Debt to assets | 2.77 | 2.77 | 3.45 | 2.66 | 3.18 | |
Net debt to EBITDA | -11.93 | -11.24 | -10.61 | -7.8 | -8.06 | |
Current ratio | 4.29 | 5.41 | 3.6 | 5.39 | 3.32 | |
Interest coverage | -6.11 | -6.27 | -7.09 | 7.77 | -8.75 | |
Income quality | 0.66 | 1.01 | 0.71 | 0.81 | 0.73 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 48.96 | 51.21 | 65.87 | 30.59 | 74.63 | |
Intangibles to total assets | 0.05 | 0.04 | 0.05 | 0.04 | 0.05 | |
Capex to operating cash flow | 0.01 | 0 | 0 | 0 | 0 | |
Capex to revenue | -0.43 | -0.01 | -0.26 | -0.11 | -0.25 | |
Capex to depreciation | -0.48 | -0.01 | -0.26 | -0.26 | -0.27 | |
Stock based compensation to revenue | 11.65 | 12 | 16.56 | 5.52 | 21.22 | |
Graham number | 14.05 | 14.47 | 13.7 | 13.43 | 12.97 | |
ROIC | -0.28 | -0.3 | -0.42 | -0.29 | -0.49 | |
Return on tangible assets | -0.26 | -0.3 | -0.33 | -0.28 | -0.32 | |
Graham Net | -9.14 | -9.02 | -7.48 | -7.92 | -8.28 | |
Working capital | 387.45M | 409.98M | 276.05M | 447.69M | 333.75M | |
Tangible asset value | -1.27B | -1.24B | -1.38B | -1.22B | -1.37B | |
Net current asset value | -1.36B | -1.34B | -1.47B | -1.3B | -1.41B | |
Invested capital | -1.38 | -1.41 | -1.28 | -1.44 | -1.28 | |
Average receivables | 20.83M | 13.92M | 9.69M | 6.89M | 3.46M | |
Average payables | 10.86M | 7.82M | 3.98M | 4.17M | 7.56M | |
Average inventory | 18.97M | 31.72M | 22.72M | 18.29M | 16.65M | |
Days sales outstanding | 821.98 | 530.39 | 472.43 | 113.74 | 90.31 | |
Days payables outstanding | 1.61K | 563.5 | 582.07 | 673.04 | 1.6K | |
Days of inventory on hand | 5.28K | 3.53K | 2.99K | 2.51K | 2.51K | |
Receivables turnover | 0.11 | 0.17 | 0.19 | 0.79 | 1 | |
Payables turnover | 0.06 | 0.16 | 0.15 | 0.13 | 0.06 | |
Inventory turnover | 0.02 | 0.03 | 0.03 | 0.04 | 0.04 | |
ROE | 0.12 | 0.14 | 0.12 | 0.15 | 0.12 | |
Capex per share | -0.01 | 0 | 0 | 0 | 0 |
BBIO Frequently Asked Questions
What is BridgeBio Pharma, Inc. stock symbol ?
BridgeBio Pharma, Inc. is a US stock , located in Palo alto of Ca and trading under the symbol BBIO
Is BridgeBio Pharma, Inc. buy or a sell ?
2 stock analysts have 2 predictions with a medium analyst target price of $18. The lowest prediction is $17 and the highest is $19
What is BBIO stock prediction ?
What is BridgeBio Pharma, Inc. stock quote today ?
BridgeBio Pharma, Inc. stock price is $30.665 today.
Is BridgeBio Pharma, Inc. stock public?
Yes, BridgeBio Pharma, Inc. is a publicly traded company.